Comparative efficacy of LDL-C-lowering therapies in first-time vs. recurrent myocardial infarction prevention: a meta-analysis of large-scale randomized controlled trials by Bao-Qiang Guo, Hong-Bin Li, Bing Zhao, Peng-Wei Xu ISBN 10.1093/EURJPC/ZWAF336 instant download

Comparative efficacy of LDL-C-lowering therapies in first-time vs. recurrent myocardial infarction prevention: a meta-analysis of large-scale randomized controlled trials by Bao-Qiang Guo, Hong-Bin Li, Bing Zhao, Peng-Wei Xu ISBN 10.1093/EURJPC/ZWAF336 instant download

Reducing elevated low-density lipoprotein cholesterol (LDL-C) is central to global efforts to prevent myocardial infarction (MI). While many studies have evaluated LDL-C-lowering therapies in first-time and recurrent MI prevention, direct comparisons of their relative efficacy are lacking. Therefore, we conducted a systematic review and meta-analysis to compare the efficacy of LDL-C-lowering therapies in first-time vs. recurrent MI prevention. 
-
Methods and results: We searched three databases until 30 November 2024, for randomized controlled trials (RCTs) with at least 1000 patient-years of follow-up. Efficacy was quantified as relative risk (RR) with 95% confidence intervals (CIs). Differences in benefit magnitude were assessed using Cochran’s Q test. Data were pooled with a random-effects model, and heterogeneity was measured using the I2 statistic.